These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32476127)

  • 1. De Novo Visual Aura Onset in a Migraineur on Galcanezumab-Gnlm.
    Kearney E; Collins T; Sengupta S
    Headache; 2020 Jul; 60(7):1435-1437. PubMed ID: 32476127
    [No Abstract]   [Full Text] [Related]  

  • 2. Galcanezumab: First Global Approval.
    Lamb YN
    Drugs; 2018 Nov; 78(16):1769-1775. PubMed ID: 30378008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injection of polidocanol foam (PF) in varicose veins as a trigger for attacks of migraine with visual aura.
    Ratinahirana H; Benigni JP; Bousser MG
    Cephalalgia; 2003 Oct; 23(8):850-1. PubMed ID: 14510934
    [No Abstract]   [Full Text] [Related]  

  • 4. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura.
    Hansen JM; Hauge AW; Olesen J; Ashina M
    Cephalalgia; 2010 Oct; 30(10):1179-86. PubMed ID: 20855363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine.
    Guo S; Christensen AF; Liu ML; Janjooa BN; Olesen J; Ashina M
    Cephalalgia; 2017 Feb; 37(2):114-124. PubMed ID: 26994300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
    Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
    Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptance and Commitment Therapy (ACT) vs Erenumab for High Frequency Episodic Migraine Without Aura: Time to Take the Gloves Off!
    Grazzi L; Rizzoli P
    Headache; 2020 Apr; 60(4):804-806. PubMed ID: 32096558
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
    Ament M; Day K; Stauffer VL; Skljarevski V; Rettiganti M; Pearlman E; Aurora SK
    J Headache Pain; 2021 Feb; 22(1):6. PubMed ID: 33549036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies.
    Oakes TM; Kovacs R; Rosen N; Doty E; Kemmer P; Aurora SK; Camporeale A
    Headache; 2020 Jan; 60(1):110-123. PubMed ID: 31721185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of a migraine aura in a patient suffering from migraine without aura.
    Marano E; Di Stasio E; Bonuso S; Chiacchio L
    Headache; 2001 Jun; 41(6):612-3. PubMed ID: 11437908
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
    Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
    Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual noise selectively degrades vision in migraine.
    Wagner D; Manahilov V; Loffler G; Gordon GE; Dutton GN
    Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2294-9. PubMed ID: 20019367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
    Detke HC; Millen BA; Zhang Q; Samaan K; Ailani J; Dodick DW; Aurora SK
    Headache; 2020 Feb; 60(2):348-359. PubMed ID: 31710104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report.
    Aradi S; Kaiser E; Cucchiara B
    J Stroke Cerebrovasc Dis; 2019 Oct; 28(10):104286. PubMed ID: 31327684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine.
    Kielbasa W; Quinlan T
    J Clin Pharmacol; 2020 Feb; 60(2):229-239. PubMed ID: 31482569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep terrors prodromal for migraine headaches responsive to galcanezumab: A case report.
    Spector AR; Kerkow JF; Collins TA
    Headache; 2021 Jan; 61(1):216-217. PubMed ID: 33382087
    [No Abstract]   [Full Text] [Related]  

  • 18. Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache.
    Scott LJ
    Drugs; 2020 Jun; 80(9):893-904. PubMed ID: 32504377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists.
    Evans RW
    Headache; 2019 Sep; 59(8):1360-1364. PubMed ID: 31310337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erenumab Plus Subcutaneous Immunoglobulin in a Patient With Comorbid Chronic Migraine and Myasthenia Gravis.
    Ornello R; Frattale I; Pistoia F; Sacco S; Notturno F
    Headache; 2020 Apr; 60(4):787-788. PubMed ID: 32096556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.